boreytinib

Boreytinib (also known as PLB1001 or bozitinib) is a potent, highly selective, small-molecule inhibitor of the c-MET (Hepatocyte Growth Factor Receptor) tyrosine kinase. Developed by Beijing Purunao Biotechnology, it is specifically designed to target cancers driven by MET alterations, including MET exon 14 skipping mutations, MET amplification, and MET fusions (such as PTPRZ1-MET). Boreytinib functions by competitively binding to the ATP-binding pocket of the MET kinase domain, thereby blocking its autophosphorylation and the activation of downstream oncogenic signaling pathways like PI3K/Akt, MAPK/ERK, and STAT3. It is currently under clinical investigation for the treatment of advanced non-small cell lung cancer (NSCLC) and recurrent glioblastoma, demonstrating the ability to cross the blood-brain barrier.

Brand names

万比锐

Other names

bozitinibPLB1001PLB-1001PLB 1001